ASH 19
Bristol-Myers Squibb drug boasts strong overall survival in acute myeloid leukaemia
December 11, 2019Research and Development ASH 19, Bristol-Myers Squibb, acute myeloid leukaemia, pharma
Bristol-Myers Squibb took the opportunity at the 2019 American Society of Hematology (ASH) Annual Meeting to reveal new efficacy data …
Takeda commits to advancing treatments for rare bleeding disorders and cancer
December 10, 2019Manufacturing and Production, Research and Development ASH 19, Cancer, Takeda, lymphoma, oncology
Takeda presented at the 61st American Society of Hematology (ASH) Annual Meeting, 29 company-sponsored abstracts to highlight its commitment to …
Sanofi to move away from diabetes and cardiovascular, as company shakeup continues
December 10, 2019Manufacturing and Production ASH 19, Sanofi, Sanofi Diabetes, Sanofi Insulin, diabetes, insulin
Sanofi has said it will stop investment and research into creating new diabetes and cardiovascular drugs, as part of the …
Janssen’s Darzalex combo shows strong overall survival benefit at ASH 2019
December 10, 2019Manufacturing and Production, Research and Development ASH 19, Janssen, darzalex, pharma
Janssen has unveiled new Phase 3 data on the efficacy of Darzalex (daratumumab) when combined with bortezomib, melphalan and prednisone …
Latest content
FibroFind appoints Lee Borthwick as CEO
July 21, 2026
